Geron stock trades 38.81 percent below its 52-week high

Published on 10/15/2026 at 20:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 57.48 million, up 11.70 percent year over year. Geron stock costs EUR 1.09 on October 15, 2026 at 8:28 p.m. CEST, up 2.94 percent on the day on Nasdaq.

Commercial scale and market position

Geron stock stood 38.81 percent below its 52-week high on October 15, 2026.
Second-quarter revenue reached USD 57.48 million, up 11.70 percent year over year.
Geron stock costs EUR 1.09 at Lang & Schwarz on October 15, 2026 at 8:28 p.m. CEST, while Nasdaq was up 2.94 percent.
Geron had approximately 1,575 prescribing accounts after the second quarter of 2026.

GERN, US3741631036, Illustration mit AI erstellt.

Geron stock stood 38.81 percent below its 52-week high of USD 2.01 on October 15, 2026, while its Nasdaq quotation rose 2.94 percent to USD 1.23. The company generated USD 57.48 million in second-quarter revenue, giving investors a clearer measure of commercial scale than the share price alone.

At Lang & Schwarz, the stock was trading at EUR 1.09 on October 15, 2026 at 8:28 p.m. CEST. The Nasdaq quotation had risen from USD 1.19 on October 14, 2026 to USD 1.23, while the euro quotation reflected the separate German trading venue.

Revenue reached USD 57.48 million

According to Benzinga, Geron reported second-quarter 2026 net revenue of USD 57.48 million, up 17.00 percent year over year and 11.00 percent from the prior quarter. The company also guided to RYTELO net product revenue of USD 220.00 million to USD 240.00 million for fiscal year 2026.

The commercial footprint expanded alongside revenue. Geron said prescribing accounts reached approximately 1,575 after the second quarter, while RYTELO demand increased 5.00 percent from the first quarter. That combination gives the revenue figure an operating marker beyond a single quarterly result.

Geron remains below its yearly high

Geron's Nasdaq quotation was USD 1.23 on October 15, 2026 at 2:33 p.m. ET, up 2.94 percent from the prior close of USD 1.19. The quote stood 18.27 percent above the 52-week low of USD 1.04 and 38.81 percent below the 52-week high of USD 2.01. Trading volume was 2,540,183 shares against an average volume of 9,866,271 shares.

Valuation stays loss-making

Geron had a market capitalization of USD 787.0 million as of October 15, 2026 and a negative price-to-earnings ratio of 12.29. Finance data also show a second-quarter 2026 net loss of USD 16.68 million and diluted earnings per share of minus USD 0.02. Cash and cash equivalents stood at USD 64.53 million on June 30, 2026.

Comparison with peers

GERN: up 2.94 percent, P/E minus 12.29, market capitalization USD 787.0 million
Insmed (Nasdaq, USD): up 0.30 percent, P/E minus 23.88, market capitalization USD 21.4 billion
Kura Oncology (Nasdaq, USD): up 1.60 percent, P/E minus 2.90, market capitalization USD 868.6 million

Commercial progress meets clinical risk

On October 12, 2026, Geron announced presentations on imetelstat at hematology meetings in Japan and German-speaking Europe, according to StockTitan. The company is balancing commercial expansion with ongoing clinical development in myelofibrosis, leaving revenue execution and trial progress as separate drivers for the stock.

Geron stock was trading at EUR 1.09 at Lang & Schwarz on October 15, 2026 at 8:28 p.m. CEST. The Nasdaq quotation was USD 1.23 on October 15, 2026 at 2:33 p.m. ET, up 2.94 percent from the prior close of USD 1.19. The further course of trading is shown by the continuously updated real-time quote of Geron stock.